Related Experiment Video

Updated: Aug 8, 2026

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
06:38

An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis

Published on: September 12, 2019

Sorafenib: recent update on activity as a single agent and in combination with interferon-alpha2 in patients with

G Kesava Reddy1, Ronald M Bukowski

  • 1CIG Media Group, LP, Dallas, TX, USA.

Clinical Genitourinary Cancer
|May 30, 2006
PubMed

Insights

Sorafenib is an effective targeted therapy for metastatic renal cell carcinoma, improving progression-free survival. This drug targets multiple tyrosine kinases involved in cancer growth and is approved for renal cancer treatment.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Metastatic renal cell carcinoma (RCC) shows poor response to conventional treatments.
  • Chemotherapy-refractory renal cancer necessitates novel therapeutic strategies.
  • Targeted therapies offer new hope for advanced kidney cancer patients.

Purpose of the Study:

  • To review the efficacy of sorafenib in treating renal cell carcinoma.
  • To discuss sorafenib's mechanism of action as a multi-kinase inhibitor.
  • To highlight sorafenib's role in managing advanced and refractory kidney cancer.

Main Methods:

  • Review of clinical trials and scientific literature on sorafenib.
  • Analysis of sorafenib's targeted inhibition of tyrosine kinases (VEGFR, PDGFR, Raf, etc.).
  • Evaluation of sorafenib's efficacy as a single agent and in combination therapies.

Main Results:

  • Sorafenib demonstrated significant improvement in progression-free survival for renal cell carcinoma.
  • The drug targets key kinases (VEGFR, PDGFR, Raf) involved in tumor proliferation and angiogenesis.
  • Sorafenib has shown clinical activity in combination studies for renal cancer.

Conclusions:

  • Sorafenib is an FDA-approved targeted therapy for renal cell carcinoma.
  • Its multi-kinase inhibition mechanism provides a novel approach to cancer treatment.
  • Ongoing trials continue to evaluate sorafenib's therapeutic potential in renal cancer.

More Related Videos

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...